Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(21/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(21/week)
News
United States
(599/week)
Manufacturing
(427/week)
Energy
(314/week)
Technology
(448/week)
Other Manufacturing
(344/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Melflufen
Jun 01, 2020
New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021
May 28, 2020
Oncopeptides Reinitiates Patient Enrollment to the Melflufen Clinical Program Following a Temporary Pause due to the COVID-19 Pandemic
May 22, 2020
Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included
May 13, 2020
Oncopeptides Announces that Two Abstracts on Multiple Myeloma have been Accepted by the 2020 ASCO Annual Meeting
Mar 26, 2020
Oncopeptides Announces 26% Overall Response Rate of Melflufen in Triple-class Refractory Multiple Myeloma Patients From the Pivotal HORIZON Study
Mar 23, 2020
The Lancet Haematology Publishes Results From Oncopeptides' Multicenter, International Phase 1/2 Study (O-12-M1)
Mar 20, 2020
Oncopeptides Provides Update Regarding COVID-19 Impact on the Melflufen Clinical Program
Dec 07, 2019
Oncopeptides Presents Updated Efficacy and Safety Data from Pivotal Phase 2 HORIZON Study in Patients With RRMM at ASH Annual Meeting 2019
Nov 06, 2019
Oncopeptides to Highlight Data From Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019
Sep 26, 2019
Patient Recruitment in the Pivotal Phase 2-Study HORIZON Completed
Sep 15, 2019
New Interim Data in RRMM Patients With Extramedullary Disease from the Pivotal Phase 2 Horizon-study Presented at International Myeloma Workshop
Aug 16, 2019
Oncopeptides Announces Acceptance of Data for Presentation at International Myeloma Workshop, September 12-15
Jun 16, 2019
New Data Presented from Oncopeptides' Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress
Jun 14, 2019
New Data Presented at 24th EHA Congress From Oncopeptides' Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)
Jun 03, 2019
New Data from Oncopeptides Phase 1/2 O-12-M1 Trial Evaluating Melflufen in RRMM Presented at 2019 ASCO Annual Meeting
May 20, 2019
Oncopeptides to Apply for Accelerated Approval in the US
May 16, 2019
Oncopeptides Announces Acceptance of Four Abstracts Highlighting Melflufen Clinical Programs for Presentation at 24th EHA Congress in June 2019
Feb 27, 2019
Data From Oncopeptides Clinical Trials HORIZON and ANCHOR Evaluating Melflufen in RRMM Selected for Presentation at the AACR Annual Meeting
Dec 02, 2018
Oncopeptides Presents First Interim Data From the Ongoing Combination Trial ANCHOR With Melflufen at the 60th American Society of Hematology Meeting
Nov 01, 2018
Oncopeptides to Present Updated Data From the Two Ongoing Trials ANCHOR and HORIZON in Patients with RRMM at ASH in December 2018
Latest News
Apr 26, 2024
OpenGate Capital Completes Sale of SMAC
Apr 26, 2024
Masonite Shareholders Approve Transaction with Owens Corning
Apr 26, 2024
Avery Dennison Increases Quarterly Dividend
Apr 26, 2024
ComEd Joins Bronzeville Community to Unveil New Public EV Chargers
Apr 26, 2024
OCOchem Advances Hydrogen Formate Electrolyzer Process By 10x To Create World’s Largest Industrial Scale CO2...
Apr 26, 2024
Canada Tractors Industry Analysis & Forecasts 2023-2024 and 2029: Technological Advancements and Shift...
Apr 26, 2024
Global and Regional Aircraft Fuel Cells Industry Research 2023-2033: Integration into Aircraft Systems Drives...
Apr 26, 2024
Leeward Renewable Energy Releases Inaugural Sustainability Highlights Report
View all News
Agenda
24
September
Hilton London Syon Park, London, UK
Defence Transformation Conference
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
View All Events